Significant associations of the TTSP genotypes with survival among patients treated with radiation therapy.

a<p><i>P</i> value from multivariate Cox analysis.</p><p>Note: Age, tumor grade, histological type, tumor size, nodal status, ER status, HER2 status, hormonal treatment, and chemotherapy were included in the analysis.</p><p>Abbreviations: OS, overall survival; BCSS, breast cancer–specific survival; RFS, recurrence-free survival, and ref., reference genotype.</p

Breast cancer–associated SNP genotypes in invasive breast cancer cases and controls.

a<p><i>P</i> (Trend); <i>P</i> value from the Armitage trend test for the overall association with invasive breast cancer risk.</p>b<p><i>P</i>, OR and CI for the homozygous allele carriers.</p>c<p><i>P</i>, OR and CI for the homozygous and heterozygous allele carriers.</p><p>Significant <i>P</i> values bolded.</p

BCSS in multivariate analysis (Cox regression).

<p>A, rs12151195; B, rs12461158; C, rs2276205; D, rs3814903; E, rs2399403 genotypes; and F, combined risk allele variable. Age, tumor grade, histological type, tumor size, nodal status, ER status, and HER2 status were included in the multivariate analysis. <i>P</i>≤0.05 was considered significant.</p

List of participating studies and number of Caucasian subjects included in at least one GxE analysis.

<p>List of participating studies and number of Caucasian subjects included in at least one GxE analysis.</p

Main effects for the epidemiologic variables included in the analyses, derived from population-based studies only¹.

<p>Main effects for the epidemiologic variables included in the analyses, derived from population-based studies only^{<a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1003284#nt104" target="_blank">1</a>}.</p

Associations between selected SNPs and breast cancer risk in Caucasians, overall and by ER status (estimated per-allele odds ratios and 95% confidence intervals)¹.

<p>Associations between selected SNPs and breast cancer risk in Caucasians, overall and by ER status (estimated per-allele odds ratios and 95% confidence intervals)^{<a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1003284#nt107" target="_blank">1</a>}.</p

Per-allele odds ratios and 95% confidence intervals for SNPs by environmental risk factors of breast cancer showing interaction P-value<10⁻³, overall and by estrogen receptor status.

<p>Per-allele odds ratios and 95% confidence intervals for SNPs by environmental risk factors of breast cancer showing interaction P-value<10⁻³, overall and by estrogen receptor status.</p

Odds ratios of gene-environment interaction for risk of breast cancer with p-value<10⁻³ by study.

<p>(A) <i>LSP1</i>-rs3817198 x Number of full-term births (among parous), (B) <i>LSP1</i>-rs3817198 x Number of full-term births (among parous), restricted to subjects not included in previous BCAC report, (C) 1p11-rs11249433 x Parous (yes/no), (D) <i>CASP8</i>-rs17468277 x mean lifetime intake of alcohol (<20 g/day versus > = 20 g/day).</p

Per-allele SNP odds ratios and 95% confidence intervals stratified by environmental risk factors of breast cancer, and combined SNP main effect.

<p>(A) <i>LSP1</i>-rs3817198 x Number of full-term births (among parous), (B) 1p11-rs11249433 x Parous (yes/no), (C) <i>CASP8</i>-rs17468277 x mean lifetime intake of alcohol (<20 g/day versus > = 20 g/day).</p

Frequencies and ORs for the c.541C>T mutation among the different patient subgroups in the Helsinki, Tampere, Oulu, and Belarus series.

<p>Frequencies and ORs for the c.541C>T mutation among the different patient subgroups in the Helsinki, Tampere, Oulu, and Belarus series.</p